Trial watch: Monoclonal antibodies in cancer therapy (Q56932681)

Jérôme Galon

3

0 references

Guido Kroemer

Guido Kroemer

6

0 references

Lorenzo Galluzzi

7

Lorenzo Galluzzi

0 references

Laurence Zitvogel

5

Laurence Zitvogel

0 references

Alexander Eggermont

2

Alexander Eggermont

0 references

Catherine Sautès-Fridman

4

Continuous cultures of fused cells secreting antibody of predefined specificity

Catherine Sautès-Fridman

0 references

language of work or name

English

0 references

publication date

1 January 2013

0 references

published in

OncoImmunology

0 references

volume

2

0 references

issue

1

0 references

page(s)

e22789

0 references

cites work

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Monoclonal antibodies: the story of a discovery that revolutionized science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial Watch: Monoclonal antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial Watch: Adoptive cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial watch: Chemotherapy with immunogenic cell death inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial watch: Dendritic cell-based interventions for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial Watch: Immunostimulatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial watch: Peptide vaccines in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Fcgamma receptors: old friends and new family members

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Molecular mechanisms of the antitumor effects of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Complement and its role in innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Revisiting the role of T cells in tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bone cancer in 2011: Prevention and treatment of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Mitotic catastrophe: a mechanism for avoiding genomic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Blinatumomab: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Insulin-like growth factor receptor inhibitors: baby or the bathwater?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment ration

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Targeting TRAIL death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Future directions in tumor immunotherapy: CTLA4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Modulation of tumor immunity by therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.22789

Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Nimotuzumab in combination with chemotherapy for patients with malignant gliomas

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Complement regulators and inhibitory proteins

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Increased exposure of anionic phospholipids on the surface of tumor blood vessels.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Molecular determinants of response to TRAIL in killing of normal and cancer cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583934

[Efficacy and adverse effets of nimotuzumab plus palitaxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer]

2 November 2018

1 reference

12 December 2020

Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions

1 reference

12 December 2020

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus

1 reference

12 December 2020

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

1 reference

12 December 2020

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 December 2020

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies

1 reference

12 December 2020

Insulin-like growth factors and the basis of growth

1 reference

12 December 2020

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

12 December 2020

Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma

1 reference

12 December 2020

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma

1 reference

12 December 2020

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

12 December 2020

1 reference

12 December 2020

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

1 reference

12 December 2020

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

12 December 2020

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

1 reference

12 December 2020

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

1 reference

12 December 2020